Table 1.
Clinical features between two groups
| Variables | Group I (n = 27) | Group II (n = 270) | P value |
|---|---|---|---|
| Age (years)) | 47.1 ± 10.5 | 48.0 ±11.3 | 0.272 |
| Sex (Male/Female) | 24/3 | 232/38 | 0.670 |
| HBsAg-positive | 26 (96.7%) | 254 (94.1%) | 0.636 |
| Anti-HCV-positive | 0 | 2 (1.2%) | 0.654 |
| Serum AFP (> 400 ng/ml) | 16 (59.3%) | 109 (40.3%) | 0.058 |
| Serum CA19-9 (> 37 U/ml) | 13 (48.1%) | 24 (8.8%) | < 0.001 |
| Serum total bilirubin (umol/L) | 116.4 ± 135.4 | 14.5 ± 7.8 | < 0.001 |
| Serum ALT (IU/L) | 132.2 ± 107.9 | 59.6 ± 53.0 | < 0.001 |
| Serum AST (IU/L) | 95.58 ± 51.5 | 60.1 ± 53.8 | < 0.001 |
| Serum albumin (g/L) | 40.4 ± 4.92 | 41.8 ± 5.6 | 0.326 |
| Serum GGT (IU/L) | 583.1 ± 372.4 | 122.9 ± 134.1 | < 0.001 |
| Serum ALP (IU/L) | 305.4 ± 148.0 | 132.2 ± 83.1 | < 0.001 |
HBsAg: hepatitis B surface antigen. HCV: hepatitis C virus. AFP: alpha-fetoprotein.
CA19-9: carbohydrate antigen19-9. BTT: biliary tumor thrombi.
ALT: alanine aminotransferase. AST: aspartate aminotransferase. GGT: γ-glutamyl transpeptidase.
ALP: alkaline phosphatase.